🔬Moderna's mRNA Vaccine Cuts Melanoma Risk by 42%
Personalized mRNA vaccines could change cancer treatment
TL;DR
Late-stage trial shows Moderna's mRNA vaccine reduces melanoma risk by 42% compared to standard treatment. This could be a game-changer for personalized cancer therapies.
Moderna and Merck's late-stage trial of a personalized mRNA vaccine against melanoma shows a 42% reduction in risk of death or recurrence compared to standard treatment. This breakthrough could redefine cancer treatment, offering a new paradigm for personalized medicine. The trial included 1,137 patients with surgically removed melanoma, showing significant improvements in recurrence-free and distant metastasis-free survival. The vaccine, intismeran (mRNA-4157), targets up to 34 unique mutations in a patient's cancer cells, marking a significant advance in melanoma treatment.
Key Points
Late-stage trial of Moderna's mRNA vaccine shows a 42% reduction in risk of death or recurrence compared to standard treatment.
Trial included 1,137 patients with surgically removed melanoma, showing significant improvements in recurrence-free and distant metastasis-free survival.
The vaccine, intismeran (mRNA-4157), targets up to 34 unique mutations in a patient's cancer cells, marking a significant advance in melanoma treatment.
At the end of the trial, 82% of the intismeran-Keytruda treatment group were alive without recurrence, while only 70% of the Keytruda-placebo group were alive without recurrence.
For distant metastasis-free survival, intismeran-Keytruda treatment reduced the risk of distant metastasis or death by 38% compared with the Keytruda-placebo group.
Why It Matters
If you're involved in cancer research or personalized medicine, this trial sets a new benchmark in the adjuvant setting. It represents one of the most significant advances in melanoma treatment since the advent of immunotherapy, offering a 42% reduction in risk of recurrence or death. This could fundamentally change how cancer is treated.
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.
Join 3,569 builders reading daily.